Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution

Trial Profile

Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Vincristine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms OPTIMAL-60; OPTIMAL>60
  • Most Recent Events

    • 06 Jun 2017 Results of pooled data of anti-infective prophylaxis with aciclovir and cotrimoxazole from two prospective DSHNHL trials (OPTIMAL > 60 and RICOVER-60) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results of a planned interim analysis (n=187) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Spectrum Pharmaceuticals media release.
    • 20 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top